StemCells said the restructuring will support the growth of the stem cell culture and cell-based assay platforms it inherited as part of its estimated $4.8 million acquisition of SCS in April.
The $4.4 million acquisition provides StemCells with cell-based drug discovery technologies.
News in brief
SCS' shareholders voted in favor of the nearly $5 million deal.
StemCells plans to invest in Stem Cell Sciences' operational facilities in Cambridge, UK, in order to provide cell-based assay services to the drug discovery industry there, according to SCS' CEO.
StemCells, which is focused on developing tissue-derived cellular products for therapeutic uses, gains cell-based drug discovery technologies through the $4.8 million deal.
Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.
The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.
US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.
In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.